Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
06/2012
06/05/2012US8192732 Mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
06/05/2012CA2557275C Bicyclo derivative
06/05/2012CA2435375C Mammalian tumor susceptibility gene products and their uses
06/05/2012CA2406278C Inhibitors of human phosphatidyl-inositol 3-kinase delta
06/05/2012CA2324226C Inhibitors of caspases
05/2012
05/31/2012WO2012071458A1 Heterocyclic inhibitors of beta - secretase for the treatment of neurodegenerative diseases
05/31/2012WO2012071414A2 Quinoxaline compounds and uses thereof
05/31/2012WO2012071279A1 Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
05/31/2012WO2012071221A2 Compositions and methods for once-daily treatment of obsessive compulsive disorder with ondansetron
05/31/2012WO2012071186A1 Modulators of s1p receptors
05/31/2012WO2012071184A1 Indole derivatives as modulators of s1p receptors
05/31/2012WO2012071152A2 Method of treating neurological conditions with extract of nerium species or thevetia species
05/31/2012WO2012071027A2 Nutraceutical based topical anxiolytic agent and method of use
05/31/2012WO2012070785A1 Sustained-release pharmaceutical composition comprising levetiracetam or pharmaceutically acceptable salt thereof having improved dissolution stability and method for manufacturing the same
05/31/2012WO2012070639A1 Neuron-specific retrograde transport vector
05/31/2012WO2012070601A1 Novel 2-alkynyl-n9-propargyladenine and medicinal use thereof
05/31/2012WO2012070114A1 Sulfamide derivative having npy y5 receptor antagonism
05/31/2012WO2012070043A1 Method and composition for weight-gain management
05/31/2012WO2012070034A1 A drug delivery device
05/31/2012WO2012070033A1 An implant for the controlled release of pharmaceutically active agents
05/31/2012WO2012070031A1 Polymeric matrix of polymer-lipid nanoparticles as a pharmaceutical dosage form
05/31/2012WO2012069790A1 Therapeutic use of compounds
05/31/2012WO2012069428A1 Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
05/31/2012WO2012068958A1 Antianxiety and sleep disorder improving use of albiflorin or metabolite thereof in
05/31/2012WO2012068783A1 Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
05/31/2012WO2012068636A1 Methods and compositions comprising antagonists of type 1 interferon-mediated signalling for reducing a neuroinflammatory response in the central nervous system
05/31/2012WO2012068630A1 Methods and compositions comprising antagonists of type 1 interferon-mediated signalling for reducing a neuroinflammatory response in the central nervous system following a stroke
05/31/2012WO2012042539A3 3 -azabicyclo [3.1.0] hexane compounds useful for the treatment of cns disorders
05/31/2012WO2012040595A9 Administration of serine protease inhibitors to the stomach
05/31/2012WO2012033789A3 Treatment of diseases
05/31/2012WO2012012712A3 Tricyclic proteasome activity enhancing compounds
05/31/2012WO2012012257A3 BIVALENT MULTIFUNCTIONAL LIGANDS TARGETING Aβ OLIGOMERS AS TREATMENT FOR ALZHEIMER'S DISEASE
05/31/2012WO2011156479A9 Trkb agonists and methods of use
05/31/2012US20120137379 Novel aav's and uses thereof
05/31/2012US20120136220 Compositions and methods for enhancing brain function
05/31/2012US20120136157 Aryl ureas as kinase inhibitors
05/31/2012US20120136065 Treatment of CNS Disorders with trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine
05/31/2012US20120136064 Methods for screening to identify therapeutic agents for alzheimer's disease and use thereof
05/31/2012US20120136050 Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
05/31/2012US20120136048 Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases
05/31/2012US20120136047 Neuroprotective compositions and methods
05/31/2012US20120136046 Method of treating age related disorders
05/31/2012US20120136045 Screening for compounds that modulate gpr3-mediated beta-arrestin signaling and amyloid beta peptide generation
05/31/2012US20120136044 Compositions And Methods Of Inhibiting NADPH Oxidase Expression
05/31/2012US20120136038 Novel Polymorphs Of Azabicyclohexane
05/31/2012US20120136037 Deuterium-enriched ruboxistaurin
05/31/2012US20120136034 Fatty acids as anti-inflammatory agents
05/31/2012US20120136028 Methods Of Diminishing Co-Abuse Potential
05/31/2012US20120136026 5-membered heterocyclic compound cyclopenta[c]pyrrolylalkylcarbamate derivatives, preparation thereof, and therapeutic use thereof
05/31/2012US20120136024 3-Substituted-2-(arlyalkyl)-1-azabicycloalkanes and Methods of Use Thereof
05/31/2012US20120136021 Oxidation-stabilized tamper-resistant dosage form
05/31/2012US20120136020 Treatment of effect of chemicals with their ultradilute stereoisomers
05/31/2012US20120136019 (s)-n-methylnaltrexone
05/31/2012US20120136018 Quinolines
05/31/2012US20120136013 Organic compounds
05/31/2012US20120136012 Amino tetrahydro-pyridopyrimidine pde10 inhibitors
05/31/2012US20120136009 Indole derivative modulators of the alpha 7 nachr
05/31/2012US20120136008 Pyrido[4,3-b]indoles and methods of use
05/31/2012US20120136007 Methods and compositions for treating degenerative and ischemic disorders
05/31/2012US20120136006 Cold menthol receptor antagonists
05/31/2012US20120136005 Eltoprazine for the treatment of anxiety
05/31/2012US20120136001 Substituted oxindole derivatives, medicaments containing the latter and use thereof
05/31/2012US20120136000 Tri-cyclic pyrazolopyridine kinase inhibitors
05/31/2012US20120135997 Pharmaceutical composition comprising a lactam or benzenesulfonamide compound
05/31/2012US20120135994 Inhibitors of human phosphatidylinositol 3-kinase delta
05/31/2012US20120135993 Cyclic triazo sodium channel blockers
05/31/2012US20120135992 Cyclic triazo sodium channel blockers
05/31/2012US20120135987 Novel phenylimidazole derivatives as pde10a enzyme inhibitors
05/31/2012US20120135982 5HT2c RECEPTOR MODULATORS
05/31/2012US20120135981 Novel substituted triazole and imidazole derivatives as gamma secretase modulators
05/31/2012US20120135980 Gamma secretase modulators
05/31/2012US20120135978 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
05/31/2012US20120135977 Ether benzotriazole derivatives
05/31/2012US20120135975 Substituted Esters as Cannabinoid-1 Receptor Modulators
05/31/2012US20120135973 Method for treating chronic pain
05/31/2012US20120135960 Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs
05/31/2012US20120135959 Metalloprotein inhibitors containing nitrogen based ligands
05/31/2012US20120135958 Tetrahydroquinoxaline urea derivatives, preparation thereof, and therapeutic use thereof
05/31/2012US20120135941 Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
05/31/2012US20120135936 Inhibition of prion protein propagation by receptor associated protein (rap), its derivatives, mimetics and synthetic peptides
05/31/2012US20120135935 Gpr54 agonists or antagonists for treatment of diseases presenting behavioral abnormalities
05/31/2012US20120135932 Compositions And Methods For Treating Ischemia And Ischemia-Reperfusion Injury
05/31/2012US20120135926 Peptides for inhibiting igf-1
05/31/2012US20120135921 Tripetide boronic acid or boronic ester, preparative method and use thereof
05/31/2012US20120135916 Monomeric and dimeric forms of adiponectin receptor fragments and methods of use
05/31/2012US20120135915 Treatment of traumatic or degenerative neurologic, otologic, or ophthalmologic diseases with targeted protease inhibitors
05/31/2012US20120135082 Extended release compositions comprising as active compound venlafaxine hydrochloride
05/31/2012US20120135077 Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
05/31/2012US20120135075 Dosage form
05/31/2012US20120135073 Oral Drug Delivery System
05/31/2012US20120135072 Oral Drug Delivery System
05/31/2012US20120135071 Abuse-proofed dosage form
05/31/2012US20120135068 Liposome-encapsulated glutathione for oral administration
05/31/2012US20120135066 Regulators of the hedgehog pathway, compositions and uses related thereto
05/31/2012US20120135048 novel formulation of indomethacin
05/31/2012US20120135041 Immunosuppressor based on the blockage of tcr-nck interaction
05/31/2012US20120135022 Assembly activating protein (aap) and its use for the manufacture of parvovirus particles essentially consisting of vp3
05/31/2012US20120135016 Induction of neurogenesis and stem cell therapy in combination with copolymer 1
05/31/2012US20120135012 Trans-membrane-antibody induced inhibition of apoptosis
05/31/2012US20120135009 Cleaved and Phosphorylated CRMP2 as Blood Marker of Inflammatory Diseases of the Central Nervous System
1 ... 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 ... 1833